Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate

Journal of Clinical Oncology

Volumn 28, Issue 9, 2010, Pages 1489-1495

  Reid, Alison H M ^a   Attard, Gerhardt ^a   Danila, Daniel C ^a   Oommen, Nikhil Babu ^a   Olmos, David ^a   Fong, Peter C ^a   Molife, L Rhoda ^a   Hunt, Joanne ^a   Messiou, Christina ^a   Parker, Christopher ^a   Dearnaley, David ^a   Swennenhuis, Joost F ^a   Terstappen, Leon W M M ^a   Lee, Gloria ^a   Kheoh, Thian ^a   Molina, Arturo ^a   Ryan, Charles J ^a   Small, Eric ^a   Scher, Howard I ^a   De Bono, Johann S ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE ACETATE; ANTIANDROGEN; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; EPLERENONE; ESTRAMUSTINE; ESTROGEN DERIVATIVE; FLUOROURACIL; GLUCOCORTICOID; GONADORELIN DERIVATIVE; KETOCONAZOLE; MITOXANTRONE; NAVELBINE; PACLITAXEL; PROSTATE SPECIFIC ANTIGEN; STEROID; ABIRATERONE; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT; STEROID 17ALPHA MONOOXYGENASE; TAXOID;

ADULT; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RESISTANCE; CASTRATION; CELL COUNT; CLINICAL ARTICLE; CONSTIPATION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FLUID RETENTION; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; LOW DRUG DOSE; MALE; MULTICENTER STUDY; NAUSEA; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR CELL; BLOOD; CLINICAL TRIAL; DRUG ANTAGONISM; MIDDLE AGED; ORCHIECTOMY; PROSTATE TUMOR;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANDROSTENOLS; ANTINEOPLASTIC AGENTS; HUMANS; MALE; MIDDLE AGED; ORCHIECTOMY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; STEROID 17-ALPHA-HYDROXYLASE; TAXOIDS;

EID: 77951518711     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.24.6819     Document Type: Article

References (27)

1. National Cancer Institute: Surveillance, Epidemiology and End Results. www.seer.cancer.gov
2. Ferlay J, Autier P, Boniol M, et al: Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18:581-592, 2007
3. Tannock IF, de Wit R, Berry WR, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512, 2004 (Pubitemid 39315317)
4. Attard G, Reid AH, A'Hern R, et al: Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 27:3742-3748, 2009
5. Attard G, Reid AH, Yap TA, et al: Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 26:4563-4571, 2008
6. Attard G, Sarker D, Reid A, et al: Improving the outcome of patients with castration-resistant prostate cancer through rational drug development. Br J Cancer 95:767-774, 2006 (Pubitemid 44498089)
7. Holzbeierlein J, Lal P, LaTulippe E, et al: Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 164:217-227, 2004 (Pubitemid 38364606)
8. Stanbrough M, Bubley GJ, Ross K, et al: Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 66:2815-2825, 2006
9. Mohler JL, Gregory CW, Ford OH 3rd, et al: The androgen axis in recurrent prostate cancer. Clin Cancer Res 10:440-448, 2004 (Pubitemid 38173980)
10. Montgomery RB, Mostaghel EA, Vessella R, et al: Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth. Cancer Res 68:4447-4454, 2008
11. Geisler J, Lonning PE: Aromatase inhibition: Translation into a successful therapeutic approach. Clin Cancer Res 11:2809-2821, 2005 (Pubitemid 40525179)
12. Hakki T, Bernhardt R: CYP17- and CYP11B-dependent steroid hydroxylases as drug development targets. Pharmacol Ther 111:27-52, 2006 (Pubitemid 43765541)
13. Setlur SR, Mertz KD, Hoshida Y, et al: Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst 100:815-825, 2008 (Pubitemid 351809667)
14. Chan FC, Potter GA, Barrie SE, et al: 3- and 4-pyridylalkyl adamantanecarboxylates: Inhibitors of human cytochrome P450(17 alpha) (17 alphahydroxylase/C17,20-lyase) - Potential nonsteroidal agents for the treatment of prostatic cancer. J Med Chem 39:3319-3323, 1996 (Pubitemid 26322857)
15. Barrie SE, Potter GA, Goddard PM, et al: Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase). J Steroid Biochem Mol Biol 50:267-273, 1994 (Pubitemid 24309119)
16. Bubley GJ, Carducci M, Dahut W, et al: Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 17:3461-3467, 1999 (Pubitemid 29517916)
17. Scher HI, Halabi S, Tannock I, et al: Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26:1148-1159, 2008
18. Allard WJ, Matera J, Miller MC, et al: Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 10:6897-6904, 2004 (Pubitemid 39383039)
19. Attard G, Swennenhuis JF, Olmos D, et al: Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res 69:2912-2918, 2009
20. Swennenhuis JF, Tibbe AG, Levink R, et al: Characterization of circulating tumor cells by fluorescence in situ hybridization. Cytometry A 75:520-527, 2009
21. Green SDS: Planned versus attained design in phase II clinical trials. Stat Med 11:853-862, 1992
22. de Bono JS, Scher HI, Montgomery RB, et al: Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 14:6302-6309, 2008
23. Olmos D, Arkenau HT, Ang JE, et al: Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): A single-centre experience. Ann Oncol 20:27-33, 2009
24. Scher HI, Jia X, de Bono JS, et al: Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: A reanalysis of IMMC38 trial data. Lancet Oncol 10:233-239, 2009
25. Ryan CJ, Smith MR, Fong L, et al: Phase I clinical trial of the CYP 17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 28:1481-1488, 2010
26. Danila DC, Morris MJ, De-Bono JS, et al: Phase II multicenter study of abiraterone acetate plus prednisone therapy in docetaxel-treated, castration-resistant prostate cancer. J Clin Oncol 28:1496-1501, 2010
27. Smaletz O, Scher HI, Small EJ, et al: Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 20:3972-3982, 2002